UG Healthcare (SGX:8K7
) has posted a lower net loss after tax of $1.4 million for 1HFY2026 ended Dec 31, 2025, an improvement of 32.5% y-o-y from $2.1 million as a result of lower foreign exchange losses.
Earnings before interest, taxes, depreciation, and amortisation (EBITA) surged more than 100% y-o-y to $3.3 million in the same period.
Revenue was up by 2.8% y-o-y to $74.7 million, mainly due to higher sales volume across all product segments and the expanded downstream distribution network.
Gross profit declined by 2.6% y-o-y to $18.3 million, primarily due to higher depreciation expenses of production lines in the third manufacturing facility which has yet to commence operations.
Correspondingly, gross profit margin declined from 25.9% in 1HFY2025 to 24.5% in 1HFY2026.
Other income increased 36.1% y-o-y to S$1.1 million due to the reversal of impairment on property, plant and equipment, which was partially offset by lower interest income.
Other expenses decreased by 67.4% y-o-y to S$0.6 million in 1HFY2026 due to the reduction in foreign exchange losses.
Net asset value per share increased to 26.53 cents as at Dec 31, 2025, due to higher net cash generated from operations and lower bank borrowings as a result of repayment.
“Excluding non-cash accounting items such as depreciation and amortisation, UG Healthcare’s EBITDA has shown significant improvement compared to the previous year,” says Lee Jun Yih, joint CEO and finance director at UG Healthcare.
See also: Tiong Woon’s 1HFY2026 earnings up 13% y-o-y to $13.6 mil
“We remain vigilant and prudent during these uncertain times, continuing to support our customers as they recover and strive to emerge stronger together,” Lee concluded.
Shares in UG Healthcare was unchanged at 9.3 cents on Feb 11.
